In Vitro Stability and Pharmacokinetics of Novel Antileishmanial Compounds by Becker, Kimberly
In Vitro Stability and Pharmacokinetics of Novel Antileishmanial 
Compounds 
 
A Senior Honors Thesis 
 
Presented in Partial Fulfillment of the  
Requirements for graduation with distinction and honors in 
Pharmaceutical Sciences  
in the undergraduate colleges of The Ohio State University 
 
 
By 
 
Kimberly N. Becker 
 
 
The Ohio State University 
 
 
Spring 2007 
 
 
Project Advisor: Dr. James T. Dalton 
Division of Pharmaceutics 
College of Pharmacy 
 
Table of Contents 
 
I. Abstract ........................................................................................................................ 3 
 
II. Introduction ..............................................................................................................3-4 
 
III. Materials and Methods ............................................................................................4-6 
 a) LC/MS/MS Method Development ..................................................................... 4 
 b) Partial Validation of TG-II-36 Analytical Method ............................................... 4 
 c) In vitro Stability of Dinitroaniline Compounds ................................................4-5 
 d) TG-II-36 in vivo Pharmacokinetic Study ........................................................5-6 
 e) BTB-06237 Analytical Method Development .................................................... 6 
 
IV. Results..................................................................................................................6-11 
 a) LC/MS/MS Method Development ..................................................................... 6 
 b) Partial Validation of TG-II-36 Analytical Method ............................................... 6 
 c) In vitro Stability of Dinitroaniline Compounds ................................................6-7 
 d) TG-II-36 in vivo Pharmacokinetic Study ........................................................7-9 
           e)  BTB-06237 Analytical Method Development..............................................9-11 
 
V.   Discussion and Conclusion................................................................................11-12 
 
VI. Acknowlegements.................................................................................................... 12 
 
VII. References ....................................................................................................……..12 
 
I. Abstract 
 
Leishmaniasis, a disease caused by protozoan parasites of the genus Leishmania, 
affects millions of people worldwide [6].  Without effective treatment, visceral leishmaniasis 
is associated with a near 100% fatality rate, whereas other forms can be severely 
debilitating [6].  Current treatments are not ideal because of toxicity, resistance, expense, 
and inconvenience [6].   
 Work to develop new drugs is underway at The Ohio State University and is led by Dr. 
Karl Werbovetz. Over the past few years Dr. Werbovetz and colleagues have generated a 
library of antiparasitic compounds known to specifically target Leishmania and trypanosome 
tubulin.  In the first round of derivatization, several dinitroanilines were synthesized and 
evaluated in in vitro efficacy and stability and in vivo efficacy studies to identify key regions 
of the molecules for efficacy and metabolism.  The most promising of these dinitroaniline 
compounds, GB-II-150, demonstrates an in vitro selectivity of two orders of magnitude for 
African trypanosomes over mammalian cell lines [7].  GB-II-150 was further evaluated in an 
in vivo metabolism study in rats [3] and found to be extensively metabolized with the major 
products resulting from N1 ring oxidation, N4 alkane oxidation, and N4 oxidation [4].  Although 
GB-II-150 had a half-life of 170 minutes with intravenous administration, it was determined 
to be highly unstable with zero oral bioavailability when given via oral gavage [3]. Based on 
the results of these studies, analogs have been prepared in effort to achieve greater 
metabolic stability while maintaining selective antiparasitic activity [4].   
A second round of derivatization and synthesis yielded another family of dinitroanilines 
that were again evaluated in vivo and in vitro for efficacy. My work has tested the in vitro 
stability and metabolism of several of these second generation dinitroaniline compounds 
that have shown antiparasitic activity.  The most promising compound from this second 
round, TG-II-36, was also tested in an in vivo stability study to determine its pharmacokinetic 
properties.  As a follow-up, ongoing work is being conducted on BTB-06237, an analog of a 
group of diphenyl thioether compounds that have also shown antiparasitic activity. This 
highly hydrophobic compound has presented serious challenges at early stages of analytical 
method development preventing adequate in vitro stability characterization.     
 
 
 
II. Introduction 
 
The leishmaniases are a globally widespread group of parasitic diseases caused by 
twenty species belonging to the genus Leishmania, a protozoa transmitted to humans 
primarily through the bite of the female sandfly [1].  This disease currently threatens 350 
million people in 88 countries, mostly located in underdeveloped regions of the world [1].  
Current treatment is expensive and available predominantly by injection or intravenous 
administration. Toxicity is a major concern for these therapies, as serious side effects and 
even death can occur. Recently, the first oral treatment for visceral leishmaniasis 
(Miltefosine) was registered in India [2].  The major concerns for this medication are cost 
and the potential development of resistance [2].  It is therefore imperative that an affordable, 
oral treatment is developed with high specificity for parasitic targets.   
Tubulin is an established target in the chemotherapy of many diseases and is essential 
to all eukaryotes [5].  Tubulin is therefore a potential drug target for the treatment of many 
infectious diseases, including leishmaniasis [5].  As stated in a recent publication, ongoing 
work focuses on the stabilization of dinitroaniline and diphenyl thioether analogs to 
metabolic inactivation while maintaining antiparasitic potency and selectivity [5].  Although 
the diphenyl thioethers showed little activity, many of the dintroanilines have displayed in 
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vitro activity against African trypanosomes, and the most active antikinetoplastid compounds 
also inhibited leishmanial tubulin [5].   
The primary goal of this research is to develop an orally active antileishmanial 
compound.  A recent publication showed that the most promising compound for in vitro 
activity and metabolic stability (GB-II-150) among a group of synthesized dinitroanilines had 
zero oral bioavailability [3].  My work has paralleled this study with the in vitro stability 
characterization of a second generation of dinitroanilines followed by a pharmacokinetic 
study in rats to determine the disposition of the most promising of evaluated compounds 
(TG-II-36) [4]. In addition, I conducted experiments with BTB- 06237, a highly hydrophobic 
diphenyl thioether analog (Table 1), to better understand difficulties encountered in 
developing an analytical method for its quantitation.   
 
 
 
III.  Materials and Methods 
 
LC/MS/MS Method Development: 
Stock solutions (1 mM) of each dinitroaniline compound were prepared in DMSO.  Stock 
solutions (1mM) of BTB-06237 were prepared in both DMSO and acetonitrile.  Solutions (5 μM) 
were prepared in acetonitrile for tuning of mass spectrometry (MS) parameters. Once MS 
parameters were tuned, injections of each compound were made to evaluate chromatography 
peak shape and retention time. GB-II-143, a previously evaluated dinitroaniline, was used as an 
internal standard for all compounds.  
 
Partial validation of TG-II-36 Analytical Method: 
To partially validate the analytical method for quantitation of TG-II-36, multiple standard curves 
were generated in rat plasma and in neat solution. To cover the concentration range expected 
from the in vivo PK experiment, multiple standard curves were created with four replicates at 
concentrations of 100 nM, 1μM, and 10 μM in rat plasma for intra-batch and inter-batch 
accuracy and precision. Our method validation efforts were directed at measuring anticipated 
concentrations between 100 nM and 10 µM. However, higher than expected concentrations 
were observed after intravenous dosing of TG-II-36, and further validation at a higher range 
(100 µM) was conducted. This work was not completed, however, due to the disappointing rapid 
elimination and apparent toxicity observed with TG-II-36. Neat standard curves were prepared 
in 50%/50% (v/v) mixtures of acetonitrile and water to determine recovery.  
 
In vitro Stability of Dinitroaniline Compounds: 
Stock solutions (1 mM) of each dinitroaniline compound were prepared.  Standard curves were 
created covering 3nM to 1000nM with triplicates at 3nM, 30nM, and 300nM in final volumes of 
330μL phosphate buffer with bovine serum albumin (BSA), pH 7.4.  An aliquot (100 μL) of each 
solution was removed and added to 1mL of acetonitrile with 10nM GB-II-143.  Tubes were then 
centrifuged and 1mL of supernatant was removed and placed in a new tube to be dried in the 
speed vac.  For the S9 and BSA reactions, a 20mM solution of NADPH in phosphate buffer was 
created and a 6μM solution of the compound was added to each.  At 0, 10, and 30 minutes 
100μL of solution were removed from each tube and quenched with acetonitrile and 10nM GB-
II-143.  Tubes were centrifuged and the supernatant was removed and placed in the speed vac.  
All samples were reconstituted in 50%/50% (v/v) acetonitrile and water and placed in 
autosampler vials for mass spectrometric analysis.   
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Table 1. Chemical structures of dinitroaniline and diphenyl thioether compounds 
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TG-II-36 in vivo pharmacokinetic study: 
Based on its improved in vitro stability compared to GB-II-150, the pharmacokinetics and 
metabolism of TG-II-36 were further characterized.  Male Sprague-Dawley rats (Harlan 
Bioscience, Indianapolis, IN) weighing between 270 g and 313 g were maintained in accordance 
with an animal protocol approved by the Institutional Laboratory Animal Care and Use 
Committee of The Ohio State University.  Animals were kept on a 12-h light/dark cycle with food 
and water ad libitum.  One day before dosing, a catheter was implanted in the right jugular vein 
of each rat, and food (Harlan Teklad 22/5 rodent diet) was removed.  The rats were supplied 
with water ad libitum and weighed immediately before dose administration.  Food was returned 
4 hr after dosing.  
 
Twelve male Sprague-Dawley rats were randomly assigned to treatment groups and received 
TG-II-36 (MW = 466 g/mol) either intravenously or orally at a dose level of 10 mg/kg.  Seven 
rats were dosed with TG-II-36 intravenously, four were dosed with TG-II-36 orally, and one was 
dosed with GB-II-150 (MW = 450 g/mol) intravenously.  Dosing solutions of 10 mg/mL were 
prepared in 5% DMSO in PEG-300 (v/v).  The jugular vein catheter was flushed with an 
aqueous solution of heparinized saline (100 U/mL, equal volume as the dosing solution and 
approximately three times the volume of the jugular vein catheter) immediately after 
administration of the intravenous dose.  Serial blood samples (c.a., 120 μL) were collected at 2, 
5, 10, 20, 30, 60, 90, 120, 240, 480, 720, and 1440 min after administration via the i.v. route, 
whereas serial blood samples (c.a. 120 μL) were obtained at 15, 30, 60, 90, 180, 240, 360, 480, 
720, and 1440 min after dosing by oral gavage.  Cannulas were flushed with 200µl 
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heparin/saline after blood draw.  Plasma was separated by centrifugation (1000×g for 15 min at 
4 °C), and samples were stored at −20 °C until analysis.  
Rats were placed in metabolic cages individually when they were used in the 
pharmacokinetic study. Urine and feces specimens were collected at 12 and 24 h.  All the 
urinary and fecal specimens were stored at −20 °C to protect against degradation. 
 
BTB-06237 Analytical Method Development: 
In addition to dinitroanilines, BTB-06237 was also selected for analysis due to its high 
antileishmanial activity with IC50 values of 0.5 ± 0.2 μM against L. donovani amastigotes [6].  
This indicates higher potency than dinitroanilines previously tested in this assay [4].  BTB-06237 
also showed selectivity by inhibiting the growth of Vero cells at higher concentrations (IC50 
values of 5.3 ± 0.5 μM ) [6].  A 1mM stock solution of BTB-06237 was prepared in acetonitrile 
for use in method development and in vitro stability. Initial studies were conducted to determine 
the linear range in neat and buffered solution and to evaluate stability in the S9 assay.   
 
IV. Results 
 
LC/MS/MS Method Development: 
An analytical method was developed for each dinitroaniline compound using an Agilent 
1100 LC system and a ThermoFinnigan TSQ Quantum Discovery Max Mass Spectrometer.  
Mobile phases consisted of 95%/5% (v/v) water/ACN (A) and 5%/95% (v/v) water/ACN (B), 
each containing 0.1% acetic acid.  An Agilent Zorbax extended C18 column (2.1 x 50 mm, 3.5 
μM) was used as the stationary phase.  Eluents were monitored via electrospray ionization in 
negative ion mode with single reaction monitoring of the parent compound.  Previously 
established gradient conditions of 50% B to 100% B between 0 and 1 minute, 100% B for 4 
minutes, 100% B to 50% B for 0.1 minute, and 50% B for equilibration for the remaining 4 
minutes of each run were used. Chromatographic separation was similar with all dinitroanilines, 
giving symmetrical peaks and elution times between 2.5 and 3.5 minutes. Linear ranges of 
quantitation between 3nM and 300nM were identified for each compound in phosphate buffer.   
Partial validation of TG-II-36 Analytical Method: 
 A partial validation of the method for quantitation of TG-II-36 was completed in the range 
of 100 nM to 10 μM in rat plasma to assure accuracy and precision in the pharmacokinetic study 
results. Inter- and intra-batch accuracy and precision are shown in Table 2.  Recovery of TG-II-
36 was also determined as 63% when comparing peak areas in neat solution vs. plasma.  
 
 Inter-batch (%) Intra-batch (%) 
Calibration level Precision Accuracy Precision Accuracy 
100 nM 11 13 17 3 
1000 nM 17 10 8 6 
10 μM 8 2 7 .1 
Table 2. Intra- and inter-batch precision and accuracy for TG-II-36. Quintuplicate 
measurements were made in each experiment (n = 5) for inter-batch, and 3 experiments 
were completed (n = 15) for inter-batch calculations. 
 
In Vitro Stability of Dinitroaniline Compounds:  
The in vitro stability of four dinitroaniline compounds (TG-III-75, TG-III-81, TG-III-86, and 
TG-II-36) was evaluated.  These compounds were synthesized based on previous data 
suggesting that a meta hydroxyl group on the N1-phenyl ring maintains parasite selectivity, 
potentially by participating in hydrogen bonding with parasitic tubulin [4].  Results are displayed 
in Figure 1 and Table 3. Although these results indicated that TG-III-75 (the only secondary 
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amine tested) was the most stable, it is significantly less active compared to the other 
compounds [4].  TG-II-36 was moderately more stable than TG-III-81 or TG-III-86 and was 
chosen for in vivo evaluation. 
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C.  TG-III-86 D.  TG-II-36 
 
Figure 1: Preliminary in vitro stability results A) TG-III-75 B) TG-III-81 and C) TG-III-86.  D) 
TG-II-36 at a final concentration of 300 nM were incubated with rat liver S9 (solid line; 1 mg/ml 
protein concentration) or bovine serum albumin (BSA, dashed line).  The concentration of each 
compound remaining at each time point was determined using LC/MS/MS. 
 
 
Compound Percent remaining at 10 minª 
TG-III-75 84 ± 7 
TG-III-81 23 ± 2 
TG-III-86 16 ± 3 
TG-II-36 45 ± 5  [4] 
Table 3. In vitro metabolism of compounds in the presence of rat liver S9  
ªValues represent means ± standard error of two triplicate experiments (n = 6). 
 
TG-II-36 in vivo pharmacokinetic study: 
TG-II-36 was poorly tolerated following intravenous dosing. One rat died during injection and 
two others died later (rat #4 died before the 4 hr time point and rat #5 died shortly after the 4 hr 
time point).  Signs of hemolysis and/or renal dysfunction were noted in most animals, with red 
discoloration observed in the urine of rats immediately (animals #2, 3, and 5), at 30 min (animal 
#15) or at 2 hr (animal #1).  Signs of hemolysis (i.e., red discoloration) were noted in the plasma 
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for animals that received TG-II-36 intravenously, but were absent from rats that received TG-II-
36 rats via oral gavage. Similar but lesser signs of hemolysis were noted for animals that 
received GB-II-150, with discoloration only noted in the urine of animal #6.  Animals #4, 7, 8, 9, 
and 14 also received GB-II-150, but produced normal urine.  Further, hemolysis was only noted 
in the plasma for the later time points after intravenous administration of GB-II-150 rats. These 
results indicated hemolysis due to TG-II-36 and to a lesser extent GB-II-150.  Rat #7 was dosed 
intravenously with 0.3 mL of the dosing vehicle (5% DMSO in PEG-300), 36 hrs after the 
original oral dose of TG-II-36, to determine if the vehicle was responsible for the observed 
hemolysis.  Blood was taken 5 min after administration of the vehicle and plasma was clear.  
The rat reacted normally to the vehicle and the urine was unchanged (no hemolysis). 
 
TG-II-36 was rapidly distributed and eliminated after intravenous administration to rats.  
Although plasma concentrations of TG-II-36 above 10 µM were observed in the early time points 
after intravenous administration, they declined below the limit of quantitation of the assay within 
four hours after dosing.  The volume of distribution of TG-II-36 was approximately 1 liter/kg, 
suggesting that it is moderately bound by plasma and tissue proteins.  The terminal elimination 
half-life for TG-II-36 was about 2 hours.  Although the systemic clearance of TG-II-36 was 16.6 
mL/min/kg, or about one-half of that previously reported for GB-II-150 [3], the mean area under 
the plasma concentration-time curve (AUC) for TG-II-36 in four rats was approximately equal to 
that observed for a single rat that received GB-II-150 in the current study.  The reason for the 
observed difference in GB-II-150 pharmacokinetics between the current and previous study is 
unknown. The high clearance of TG-II-36 suggests that it undergoes extensive hepatic 
metabolism and extraction.  Accordingly, plasma concentrations of TG-II-36 were detectable but 
below the limit of quantitation after oral administration to rats.   
 
Parameter GB-II-150  
previous 
data  
GB-II-150 TG-II-36 NCA 
 
t½β (terminal half life) (min) 170  42 124 ± 7.6 
AUC (min µg/mL) 285 ± 69  620 713 ± 213 
CL (mL/min/kg) 31.5 ± 7.0  15.9 16.6 ± 4.2 
Vss (mL/kg) 4981 ± 1757 539 981 ± 433 
               Table 4. Pharmacokinetics of GB-II-150 and TG-II-36 after intravenous 
administration of 10 mg/kg, values are mean ± S.E. (n=4) except GB-II-150 where only one 
rat was used.  Noncompartmental analysis (NCA) was used for all GB-II-150 rats (Wu, et 
al., 2006). 
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Figure 2                                                                                
(A) Average concentrations for four intravenous TG-II-36 rats and one GB-II-150 rat ranging 
from 2-240 min.  All other time points (480-1440 min) were below the quantitation limit and the 
240 time point for the GB-II-150 rat was below the quantitation limit. (B) Concentrations for all 
intravenous TG-II-36 rats and one GB-II-150 rat ranging from 2-240 min.      
  
 
BTB-06237 Analytical Method Development:   
Evaluation of BTB-06237 in the S9 assay produced poor results. With a concentration 
range between 3 nM and 300 nM, the same range used for the aforementioned dinitroaniline 
compounds, linearity was not consistently observed for BTB-06237 in neat solution, and it was 
undetectable in S9 reaction buffer. Additional experiments were therefore added to understand 
the difficulties encountered with the use of this compound in our existing metabolic stability 
assays. 
Aqueous solubility was suspected as a potential cause for the poor sensitivity observed 
in standard and reaction samples. An early study was conducted to evaluate the use of Pluronic 
F-127, a polymer that had shown promise for increasing BTB-06237 solubility in water, to 
determine its utility in method development and S9 reactions. However, results with this polymer 
were indistinguishable when compared to the control without F-127 (data not shown). A study 
was therefore conducted to compare BTB-06237 signal intensity in various solvents to assure 
stock solutions, reaction solution, extraction and reconstitution solvents were appropriate. 
Figure 3 displays the results from this study. Although acetone provided the highest signal for 
BTB, good signal intensity was observed for all organic solvents tested. BTB-06237 produced 
very low signal in water, indicating potentially poor solubility and possible precipitation. 
However, given that aqueous solubility was apparently adequate for IC50 determinations during 
in vitro efficacy assays in the micro-molar range [6], we evaluated the use of higher 
concentrations for quantification. Results were mixed as we identified a linear range at these 
higher concentrations, but signal intensity was very low in S9 phosphate reaction buffer 
compared to neat solution. Figure 4, plot 1 displays the linearity and chromatographic peak 
areas achieved between 300 nM and 30 μM in neat solution. The remaining plots indicate the 
lower signal in phosphate buffer (plots 2A and 2B) and water (3). 
Further experiments were conducted at the higher concentration range to better 
understand the causes for poor signal intensity in aqueous solution. These studies focused on 
solubility, stability and matrix ion suppression effects. These experiments included the 
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evaluation of sample vial (glass vs. plastic), addition of vitamin C to stabilize BTB-06237, and 
stability during processing (extraction, drying and storage). Figure 4, plots 2A, 2B and 3, 
illustrate results from one of these studies. When phosphate is included in the sample (plot 2A), 
some signal suppression is observed compared to water alone (plot 3) indicating a slight matrix 
effect. This plot also illustrates that some signal loss occurs when comparing before (plot 2A) 
and after sample drying in the vacuum evaporator (plot 2B). Further work is planned to evaluate 
the time required for BTB-06237 to dissolve in water as a potential source of variation in our 
assays. BTB-06237 has proven difficult to work with in vitro due to an apparent low solubility or 
stability in aqueous environments (buffer and/or plasma).   
 
BTB-06237 Solubility
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 Figure 3. 1μM solutions of BTB-06237 in various solvents: BTB-06237 (1mM in DMSO) 
was added to a each solvent to produce a 1μM solution. Samples were injected into the 
LC/MS/MS method for separating and detecting BTB-06237, and chromatographic peak 
areas (y-axis) were observed for comparison. 
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Figure 4. Standard curves of BTB-06237 in neat solution (1), phosphate buffer (2A and 
2B), and water. Signal loss was evaluated by adding BTB-06237 at different steps in the 
sample preparation process. As an example, plot 2B indicates some signal loss during 
the drying process in the vacuum evaporator (compared to 2A). Plot 2A indicates a 
potential matrix effect when compared to plot 3 (phosphate buffer vs. no buffer). (y-axis 
is chromatographic peak area). 
 
V. Discussion and Conclusion 
 
We successfully developed accurate and sensitive LC/MS/MS methods for the 
quantitation of several novel dinitroanilines.  We used these methods to study the in vitro 
stability of four compounds in the presence of bovine serum albumin (protein control) and 
hepatic S9 fractions from the rat liver. Pilot studies to develop an analytical method for a 
diphenyl thioether, BTB-06237, were also conducted.  Lastly, we evaluated the in vivo 
pharmacokinetics of one dinitroaniline, TG-II-36, after intravenous and oral dosing to rats. 
The pattern of N4 substitution had little to no influence on the in vitro metabolic stability 
of the four dinitroanilines studied; with the exception that the one secondary amine tested (TG-
III-75) was the most stable and least active of the compounds tested. TG-II-36 was the most 
stable of the remaining three compounds, but was also extensively metabolized during in vitro 
incubation with S9 hepatic fractions (i.e., only 45% remaining at 10 minutes). 
Pharmacokinetic studies of TG-II-36 showed that it was moderately distributed and 
rapidly cleared after intravenous administration, while oral dosing studies demonstrated that 
less than 5% of the dose appeared in the systemic circulation after oral gavage.  We therefore 
conclude that TG-II-36 has limited oral bioavailability.  When compared to GB-II-150, TG-II-36 
appears to be more toxic.  Three rats died during the course of the pharmacokinetic studies.  
Almost all intravenous rats experienced hemolysis.  Rats injected with GB-II-150 experienced 
slight hemolysis during a previous study (Wu et al., 2006), but it was not as severe or as rapid 
onset as the rats injected with TG-II-36 in our study.  Although TG-II-36 appeared to be more 
stable in vitro than GB-II-150, it appeared to have comparable stability in vivo. 
The class of diphenyl thioether compounds, including BTB-06237, do not seem to target 
tubulin and do not work in the previous dinitroaniline in vitro stability assay.  Our pilot studies 
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show that the type of tubes used (plastic vs. glass) do not have a significant affect on the mass 
spectrometry results.  It is possible that some of the compound may be degraded during sample 
processing or that it is unable to be fully detected upon LC/MS/MS analysis because of matrix 
effects.  Further work with these compounds may prove to be very difficult given solubility and 
analytical method development issues.  Work with this compound and others will continue in the 
lab. 
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